Astrazeneca PLC (NYSE:AZN) – Jefferies Group decreased their FY2016 earnings per share (EPS) estimates for shares of Astrazeneca PLC in a research report issued to clients and investors on Thursday. Jefferies Group analyst J. Holford now anticipates that the firm will earn $2.01 per share for the year, down from their prior forecast of $2.07. Jefferies Group has a “Buy” rating on the stock. Jefferies Group also issued estimates for Astrazeneca PLC’s FY2017 earnings at $2.03 EPS.
Several other brokerages have also recently commented on AZN. Cantor Fitzgerald reissued a “buy” rating on shares of Astrazeneca PLC in a research report on Monday, August 8th. JPMorgan Chase & Co. reissued a “neutral” rating on shares of Astrazeneca PLC in a research report on Monday, August 8th. Piper Jaffray Cos. began coverage on shares of Astrazeneca PLC in a research report on Friday, September 23rd. They issued an “overweight” rating for the company. Citigroup Inc. reissued a “buy” rating on shares of Astrazeneca PLC in a research report on Wednesday, August 10th. Finally, Deutsche Bank AG reissued a “buy” rating on shares of Astrazeneca PLC in a research report on Wednesday, September 28th. Three research analysts have rated the stock with a sell rating, nine have assigned a hold rating, ten have given a buy rating and two have issued a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $37.56.
Shares of Astrazeneca PLC (NYSE:AZN) opened at 30.59 on Monday. Astrazeneca PLC has a 12-month low of $26.97 and a 12-month high of $35.04. The stock has a market capitalization of $77.39 billion, a price-to-earnings ratio of 34.96 and a beta of 0.75. The firm has a 50-day moving average of $32.87 and a 200 day moving average of $30.88.
Astrazeneca PLC (NYSE:AZN) last announced its quarterly earnings data on Thursday, July 28th. The company reported $0.83 earnings per share for the quarter, beating analysts’ consensus estimates of $0.76 by $0.07. The firm had revenue of $5.60 billion for the quarter, compared to analyst estimates of $5.56 billion. Astrazeneca PLC had a net margin of 9.23% and a return on equity of 28.02%. The business’s quarterly revenue was down 4.0% compared to the same quarter last year. During the same period in the previous year, the company earned $1.21 earnings per share.
A number of hedge funds have recently added to or reduced their stakes in AZN. Forester Capital Management LTD increased its stake in Astrazeneca PLC by 68.4% in the first quarter. Forester Capital Management LTD now owns 3,200 shares of the company’s stock worth $109,000 after buying an additional 1,300 shares in the last quarter. First Interstate Bank increased its stake in shares of Astrazeneca PLC by 233.3% in the second quarter. First Interstate Bank now owns 3,900 shares of the company’s stock valued at $118,000 after buying an additional 2,730 shares during the period. Synovus Financial Corp increased its stake in shares of Astrazeneca PLC by 29.7% in the second quarter. Synovus Financial Corp now owns 4,372 shares of the company’s stock valued at $132,000 after buying an additional 1,000 shares during the period. Fifth Third Bancorp increased its stake in shares of Astrazeneca PLC by 2.3% in the second quarter. Fifth Third Bancorp now owns 4,631 shares of the company’s stock valued at $140,000 after buying an additional 103 shares during the period. Finally, Integrated Investment Consultants LLC increased its stake in shares of Astrazeneca PLC by 6.1% in the second quarter. Integrated Investment Consultants LLC now owns 4,756 shares of the company’s stock valued at $144,000 after buying an additional 275 shares during the period. 11.46% of the stock is currently owned by hedge funds and other institutional investors.
About Astrazeneca PLC
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.
Receive News & Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related companies with MarketBeat.com's FREE daily email newsletter.